Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes

Sponsor
Chung Shan Medical University
Study ID
NCT07708610
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Pneumonia
  • Type 2 Diabetes Mellitus (T2DM)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare preadmission glucose-lowering treatment strategies in adults with type 2 diabetes hospitalized with pneumonia. Time zero is the date of the index pneumonia admission. The study compares patients with evidence of prescriptions for both a GLP-1 receptor agonist and an SGLT2 inhibitor in the year before admission with patients prescribed a GLP-1 receptor agonist alone, an SGLT2 inhibitor alone, or usual care. Usual care includes metformin, sulfonylureas, or DPP-4 inhibitors without either study class. The primary outcome is a composite of all-cause death, invasive mechanical ventilation, or renal replacement therapy within 30 days of admission, with the individual components and 12-month mortality, major adverse cardiovascular events, and major adverse kidney events also evaluated. Propensity-score methods are used to reduce bias from nonrandom treatment selection.

Key Dates

First listed
Jul 16, 2026
Start date
Jul 31, 2026
Status verified
Jul 2026
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
71,775 participants (estimated)

Arms

  • Arm: GLP-1 RA plus SGLT2i
    Adults with type 2 diabetes hospitalized with pneumonia who had prescriptions for both a GLP-1 receptor agonist and an SGLT2 inhibitor in the year before admission.
  • Arm: GLP-1 RA alone
    Adults with type 2 diabetes hospitalized with pneumonia who had a prescription for a GLP-1 receptor agonist, and no prescription for an SGLT2 inhibitor, in the year before admission.
  • Arm: SGLT2i alone
    Adults with type 2 diabetes hospitalized with pneumonia who had a prescription for an SGLT2 inhibitor, and no prescription for a GLP-1 receptor agonist, in the year before admission.
  • Arm: Usual care
    Adults with type 2 diabetes hospitalized with pneumonia who had a prescription for metformin, a sulfonylurea, or a DPP-4 inhibitor, and no prescription for a GLP-1 receptor agonist or an SGLT2 inhibitor, in the year before admission.

Primary Outcome Measure

Composite outcome (all-cause mortality, invasive mechanical ventilation, or renal replacement therapy) [ Time Frame: Within 30 days after the index pneumonia admission ]

Central Contacts

Related Studies